Skip to main content

Table 3 The univariate cox regression analysis in cervical cancer patients

From: Connecting METTL3 and intratumoural CD33+ MDSCs in predicting clinical outcome in cervical cancer

Factors Disease-free survival Overall survival
HR (95%CI) P value HR (95%CI) P value
The levels of METTL3, CD33 in tumor and tumor-infiltrating immune cells (n = 197)
 Age, years (≤ 44/ > 44) 0.937 (0.405–2.169) 0.879 1.281 (0.581–2.825) 0.539
 Clinical stage (I/II–IV) 3.511 (1.472–8.373) 0.005 3.820 (1.702–8.573) 0.001
 Tumor (T) status (1/2–4) 0.128 (0.017–0.955) 0.051 0.106 (0.014–0.783) 0.058
 Nodal (N) status (0/1) 2.798 (1.095–7.152) 0.032 2.225 (0.893–5.542) 0.086
 METTL3 in tumor cells (low/high) 4.244 (1.730–10.413) 0.002 5.502 (2.312–13.092) 0.001
 METTL3 in tumor-infiltrating immune cells (low/high) 4.857 (1.643–14.353) 0.004 6.021 (2.074–17.474) 0.001
 Number of CD33+ MDSCs (low/high) 6.579 (1.946–22.241) 0.002 5.755 (1.982–16.705) 0.001
 Combination of METTL3 levels and CD33+MDSCs (low/ middle/ high) 4.672(2.149–10.156)  < 0.001 4.890(2.369–10.093)  < 0.001
The levels of METTL3, CD33 in tumor and tumor-infiltrating immune cells in stage I (n = 127)
 Age, years (≤ 44/ > 44) 0.364 (0.074–1.807) 0.217 0.562 (0.140–2.250) 0.416
 Tumor (T) status (1/2–4) 0.033 (0.00–35.599) 0.338 0.032 (0.000–22.782) 0.305
 Nodal (N) status (0/1) 2.736 (0.552–13.569) 0.218 2.325 (0.483–11.20) 0.293
 METTL3 in tumor cells (low/high) 1.696 (0.424–6.783) 0.455 2.184 (0.586–8.132) 0.244
 METTL3 in tumor-infiltrating immune cells (low/high) 6.489 (0.799–52.832) 0.080 7.452 (0.932–59.588) 0.058
 Number of CD33+ MDSCs (low/high) 1.732 (0.414–7.250) 0.452 2.085 (0.521–8.339) 0.299
 Combination of METTL3 levels and CD33+MDSCs (low/ middle/ high) 2.639 (0.896–7.775) 0.078 3.071(1.056–8.931) 0.039
The levels of METTL3, CD33 in tumor and tumor-infiltrating immune cells in stage II–IV (n = 70)
 Age, years (≤ 44/ > 44) 0.953 (0.299–3.039) 0.935 1.240 (0.404–3.804) 0.707
 Tumor (T) status (1/2–4) 0.145 (0.019–1.110) 0.063 0.116 (0.015–0.874) 0.537
 Nodal (N) status (0/1) 2.554 (0.800–8.152) 0.113 1.192 (0.623–5.869) 0.257
 METTL3 in tumor cells (low/high) 9.713 (2.697–34.978) 0.001 13.199 (3.776–46.130)  < 0.001
 METTL3 in tumor-infiltrating immune cells (low/high) 5.373 (1.498–19.276) 0.010 7.209 (2.070–25.106) 0.002
 Number of CD33+ MDSCs (low/high) 66.197 (0.891–4917.536) 0.056 16.621 (2.199–125.660) 0.006
 *Combination of METTL3 levels and CD33+MDSCs (low/ middle/ high) 7.673 (2.420–24.324) 0.001 7.286(2.667–19.902)  < 0.001
  1. HR hazard ratio, 95%CI 95% confidence interval
  2. *Since combined expression of METTL3 and CD33 in tumor-infiltrating immune cells is divided into three groups (low/middle/high), it is no longer calculated in multivariate analysis